Apoptosis induced by sulindac sulfide in epithelial and mesenchymal cells from human abdominal neoplasms

European Journal of Pharmacology

Volumn 360, Issue 1, 1998, Pages 105-112

  Picariello, Lucia ^a   Brandi, Maria Luisa ^a   Formigli, Lucia ^a   Orlandini, Sandra Zecchi ^a   Dolara, Piero ^a   Caderni, Giovanna ^a   Raimondi, Laura ^a   Tonelli, Francesco ^a  

^a Dept Clin Physiopathology U ^*  (Italy)

Author keywords

Apoptosis; Colorectal cancer; Sulindac sulfide

Indexed keywords

SULINDAC SULFIDE;

ABDOMINAL CANCER; ANIMAL CELL; APOPTOSIS; ARTICLE; CATTLE; CELL GROWTH; CELL PROLIFERATION; COLON TUMOR; COLORECTAL CANCER; CONTROLLED STUDY; DESMOID TUMOR; DOSE RESPONSE; EPITHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; MESENCHYME CELL; NONHUMAN; PRIORITY JOURNAL;

ABDOMINAL NEOPLASMS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL LINE; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; HUMANS; MESODERM; SULINDAC; TUMOR CELLS, CULTURED;

EID: 0032582544     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00665-7     Document Type: Article

References (31)

1. Belliveau P., Graham A.M. Mesenteric desmoid tumor in Gardner's syndrome treated by sulindac. Dis. Colon Rectum. 27:1984;53-54.
2. Boolbol S.L., Dannenberg A.J., Chadburn A., Martucci C., Guo X.J., Ramonetti J.T., Abreu-Goris M., Newmark H.L., Lipkin M.L., De Cosse J.J., Bertagnoli M.M. Cyclo-oxygenase 2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 56:1996;2556-2560.
3. Burton K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. J. Biochem. 62:1956;315-322.
4. Charalambous D., O'Brien P.E. Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis. Gastroenterol. Hepatol. 11:1996;307-310.
5. Du Bois R.N., Shao J., Tsujii M., Sheng H., Beauchamp R.D. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res. 56:1996;733-737.
6. Duggan D.E., Hare L.B., Dizler C.A., Lei B.W., Kwan K.C. The disposition of sulindac in man. Clin. Pharmacol. Exp. Ther. 21:1977;326-335.
7. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119:1992;493-501.
8. Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Celano P.S., Booker V., Robinson C.R., Offeratus G.J.A. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328:1993;1313-1316.
9. Giovannucci E., Rimm E.B., Stampfer M.J., Colditz G.A., Ascherio A., Willet W.C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. 21:1994;241-246.
10. Goldberg Y., Nassif I.I., Pittas A., Tsai L.L., Dynlacht B.D., Rigas B., Shiff S.J. The anti-proliferative effect of sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene. 12:1996;893-901.
11. Hanif R., Pittas A., Feng Y., Koutsos M.I., Quiao L., Staiano-Coico L., Shiff S.I., Rigas B. Effects of non steroidal anti-inflammatory drugs on proliferation and induction of apoptosis in colon cancer cells by a prostaglandin independent pathway. Biochem. Pharmacol. 52(2):1996;237-245.
12. Hubbard W.C., Alley M.C., McLemore T.L., Boyd M.R. Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate and ovarian tumors. Cancer Res. 18:1988;1770-1775.
13. 2α. Proc. Natl. Acad. Sci. USA. 72:1975;2724-2728.
14. Oshima M., Dinchuk J.E., Kargam S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., Taketo M.M. Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclo-oxygenase 2 (COX-2). Cell. 87:1996;803-809.
15. Piazza G.A., Rahm A.L.K., Krutzsch M., Sperl G., Paranka N.S., Gross P.H., Brendel K., Burt R.W., Alberts D.S., Pamukeu R., Ahnen D.J. Anti-neoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 55:1995;3110-3116.
16. Picariello L., Fiorelli G., Benvenuti S., Brandi M.L., Galli G., Malentacchi C., Montali E., Bigozzi U., Ficari F., Tonelli F. 'In vitro' bioeffects of the anti-estrogen LY117018 on desmoid tumor and colon cancer cells. Anticancer Res. 17:1997;2029-2104.
17. Ravis W.R., Diskun C.J., Campagna K.D., Clark C.R., Mc Millian C.L. Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure. J. Clin. Pharmacol. 33:1993;527-534.
18. Rigas B., Goldman J.S., Levine L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 122:1993;518-523.
19. Schnitzler M., Dwight T., Robinson B.G. Sulindac increases the expression of APC mRNA in malignant colonic epithelial cells: an in vitro study. Gut. 38:1996;707-713.
20. Shen T.Y., Winter C.A. Chemical and biological studies of indomethacin, sulindac and their analogs. Adv. Drug Res. 12:1977;90-245.
21. Shiff S.J., Quiao L., Tsai L., Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest. 96:1995;491-503.
22. Spagnesi M.T., Tonelli F., Dolara P., Caderni G., Valanzano R., Anastasi A., Bianchini F. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology. 106:1994;362-366.
23. Stang H.A., Warner N.J., Renwick A.G., George C.F. Sulindac metabolism: the importance of an intact colon. Clin. Pharmacol. Ther. 38:1985;387-393.
24. Streeten E.A., Ornberg R., Curcio F., Sakaguchi K., Marx S., Aurbach G.D., Brandi M.L. Cloned endothelial cells from fetal bovine bone. Proc. Natl. Acad. Sci. USA. 86:1989;916-920.
25. Thompson H.J., Jiang C., Lu J., Metha R.G., Piazza G.A., Paranka N.S., Pamukcu R., Ahnen D.J. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 57:1997;267-271.
26. Tonelli F., Valanzano R. Sulindac in familial adenomatous polyposis. Lancet. 342:1993;1120.
27. Tonelli F., Valanzano R., Brandi M.L. Pharmacologic treatment of desmoid tumors in familial adenomatous polyposis: results of an in vitro study. Surgery. 15:1994;473-479.
28. Vane J.R. Inhibition of prostaglandine synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol. 231:1977;232-235.
29. Waddel W.R., Gerner R.E., Reich M.P. Nonsteroid anti-inflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach. J. Surg. Oncol. 22:1983;197-211.
30. Waddel W.R., Gasner G.F., Cerise E.J., Loughry R.W. Sulindac for polyposis of the colon. Am. J. Surg. 157:1989;176-178.
31. Wyllie A.H. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature. 284:1980;555-556.